山东新华制药股份(00719.HK)：子公司获得布洛芬颗粒药品注册证书

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its ibuprofen granules, indicating a significant development in its product portfolio and potential market expansion [1] Group 1: Company Announcement - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has been granted a drug registration certificate for ibuprofen granules [1] - The approved product is intended for the relief of mild to moderate pain, including headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, dysmenorrhea, and fever caused by common colds or influenza [1]